We could not find any results for:
Make sure your spelling is correct or try broadening your search.
Register for Free to get streaming real-time quotes, interactive charts, live options flow, and more.
| Share Name | Share Symbol | Market | Type | Share ISIN | Share Description |
|---|---|---|---|---|---|
| Circassia Group Plc | LSE:CIR | London | Ordinary Share | GB00BJVD3B28 | ORD 0.08P |
| Price Change | % Change | Share Price | Bid Price | Offer Price | High Price | Low Price | Open Price | Shares Traded | Last Trade | |
|---|---|---|---|---|---|---|---|---|---|---|
| 0.00 | 0.00% | 34.00 | 33.10 | 34.90 | 0.00 | 01:00:00 |
| Industry Sector | Turnover | Profit | EPS - Basic | PE Ratio | Market Cap |
|---|---|---|---|---|---|
| 0 | 0 | N/A | 0 |
From Apr 2022 to Apr 2024
By Kyle Morris
Shares in Circassia Group PLC rose Wednesday after it said that it is entitled to receive payments of $10.5 million following Beyond Air Inc.'s confirmation that it had received approval from the Food and Drug Administration for its LungFit PH device for the treatment of hypoxic respiratory failure in newborn children.
Shares at 1027 GMT were up 3.00 pence, or 9.1%, at 35.90 pence.
The U.K. medical-device company said, thanks to an agreement with Beyond Air, it is entitled to receive $2.5 million within 60 days of approval, $3.5 million within 60 days of the first anniversary of approval, and $4.5 million within 60 days of the second anniversary of approval. Furthermore, Circassia is entitled to a royalty of 5% of net sales of the device, starting on the second anniversary of approval, up to a maximum of $6 million, it said.
Write to Kyle Morris at kyle.morris@dowjones.com
(END) Dow Jones Newswires
June 29, 2022 06:44 ET (10:44 GMT)
Copyright (c) 2022 Dow Jones & Company, Inc.
1 Year Circassia Chart |
1 Month Circassia Chart |
It looks like you are not logged in. Click the button below to log in and keep track of your recent history.
Support: +44 (0) 203 8794 460 | support@advfn.com
By accessing the services available at ADVFN you are agreeing to be bound by ADVFN's Terms & Conditions
Hot Features
Premium
